ATE427758T1 - Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen - Google Patents

Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen

Info

Publication number
ATE427758T1
ATE427758T1 AT03735232T AT03735232T ATE427758T1 AT E427758 T1 ATE427758 T1 AT E427758T1 AT 03735232 T AT03735232 T AT 03735232T AT 03735232 T AT03735232 T AT 03735232T AT E427758 T1 ATE427758 T1 AT E427758T1
Authority
AT
Austria
Prior art keywords
reactions
inhibitor
inflammable
inhibit
chemotactic factor
Prior art date
Application number
AT03735232T
Other languages
English (en)
Inventor
Philippe Tessier
Carle Ryckman
Karen Vandal
Pascal Rouleau
Original Assignee
Univ Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Laval filed Critical Univ Laval
Application granted granted Critical
Publication of ATE427758T1 publication Critical patent/ATE427758T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03735232T 2002-07-05 2003-06-20 Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen ATE427758T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39352002P 2002-07-05 2002-07-05

Publications (1)

Publication Number Publication Date
ATE427758T1 true ATE427758T1 (de) 2009-04-15

Family

ID=30115596

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03735232T ATE427758T1 (de) 2002-07-05 2003-06-20 Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen

Country Status (7)

Country Link
US (4) US7553488B2 (de)
EP (1) EP1519749B1 (de)
AT (1) ATE427758T1 (de)
AU (1) AU2003236762A1 (de)
CA (1) CA2489860C (de)
DE (1) DE60327075D1 (de)
WO (1) WO2004004770A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004084928A1 (en) * 2003-03-28 2004-10-07 UNIVERSITé LAVAL S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
WO2006005186A1 (en) * 2004-07-13 2006-01-19 UNIVERSITé LAVAL S100 protein inhibitors for treating leukemia
WO2006122723A1 (en) * 2005-05-19 2006-11-23 Vaecgene Biotech Gmbh Method for the prevention and/or treatment of autoimmune disease or allogeneic transplant rejections
ES2654542T3 (es) 2008-04-30 2018-02-14 Genomix Co., Ltd. Procedimiento de recolección de células funcionales in vivo con alta eficiencia
KR20110027665A (ko) * 2008-04-30 2011-03-16 가부시키가이샤 제노믹스 손상조직의 기능적 재생 촉진 의약
US8283131B2 (en) * 2008-10-28 2012-10-09 Assistance Publique-Hopitaux De Paris Methods and kits for the rapid determination of patients at high risk of death during severe sepsis and septic shock
EP2494977B1 (de) 2009-10-28 2018-06-13 Genomix Co., Ltd. Geweberegenerationsförderer mit rekrutierung mesenchymaler knochenmarkstammzellen und/oder pluripotenter stammzellen in blut
WO2012056044A1 (en) 2010-10-30 2012-05-03 Imperial Innovations Ltd Treatment for dupuytren's disease
WO2012147470A1 (ja) 2011-04-26 2012-11-01 株式会社ジェノミックス 組織再生を誘導するためのペプチドとその利用
WO2012155049A1 (en) * 2011-05-11 2012-11-15 Medimmune, Llc Treatment of lung inflammation
EP2913059B1 (de) 2012-10-25 2018-04-11 Genomix Co., Ltd. Neuartiges verfahren zur behandlung von rückenmarksverletzungen mit hmgb1-fragmenten
MX361259B (es) 2012-10-25 2018-11-30 Univ Osaka Uso de un fragmento de peptido hmgb1 para el tratamiento del infarto al miocardio.
US10005833B2 (en) * 2015-01-02 2018-06-26 Washington State University Methods of treating inflammation associated airway diseases and viral infections
EA201990253A1 (ru) * 2015-07-13 2019-06-28 Юниверсите Лаваль Гуманизированные антитела против s100a9 и их применение
EA038980B1 (ru) * 2015-09-14 2021-11-17 Юниверсите Лаваль Анти-s100a8 для лечения лейкемии
EP4215210A1 (de) 2016-04-08 2023-07-26 180 Therapeutics LP Verfahren zur behandlung der dupuytren-krankheit im frühstadium
US11969459B2 (en) 2017-01-27 2024-04-30 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
KR102457657B1 (ko) 2017-02-07 2022-10-21 리프스톤 비.브이. 무균성 해리로 인한 임플란트 관련 임플란트 교정 위험을 진단하기 위한 바이오마커
US12566174B2 (en) 2017-05-11 2026-03-03 The Research Foundation For The State University Of New York Method and kit for determining the presence of monosodium urate crystals in joint synovial fluid
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease
US12421498B2 (en) 2017-12-01 2025-09-23 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
EP3750553A4 (de) 2018-02-08 2022-01-12 Stemrim Inc. Therapeutikum für psoriasis
WO2020051460A1 (en) * 2018-09-07 2020-03-12 Sanford Burnham Prebys Medical Discovery Institute Methods of diagnosis and treatment of inflammatory bowel disease
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3789413T2 (de) 1986-10-03 1994-07-28 Ciba Geigy Ag Lymphokin-ähnliche Peptide.
SG66214A1 (en) * 1990-09-05 1999-07-20 Heart Research Inst Ltd Novel chemotactic factor
US5248825A (en) * 1990-09-20 1993-09-28 Merrell Dow Pharmaceuticals Inc. Calcium uptake inhibitors
AU6111298A (en) * 1997-02-12 1998-09-08 Samir M. Hanash Protein markers for lung cancer and use thereof
US5849528A (en) * 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
WO2000018970A1 (fr) * 1998-09-29 2000-04-06 Asahi Kasei Kabushiki Kaisha Procede de commande de liberation de granules
US20050118688A1 (en) * 2001-12-28 2005-06-02 Hudson Freeze Novel ligand involved in the transmigration of leukocytes across the endothelium and uses therefor
WO2004084928A1 (en) * 2003-03-28 2004-10-07 UNIVERSITé LAVAL S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
WO2006005186A1 (en) * 2004-07-13 2006-01-19 UNIVERSITé LAVAL S100 protein inhibitors for treating leukemia

Also Published As

Publication number Publication date
AU2003236762A1 (en) 2004-01-23
EP1519749B1 (de) 2009-04-08
US20090275516A1 (en) 2009-11-05
CA2489860A1 (en) 2004-01-15
CA2489860C (en) 2015-02-10
US20140348849A1 (en) 2014-11-27
WO2004004770A1 (en) 2004-01-15
US8282925B2 (en) 2012-10-09
DE60327075D1 (de) 2009-05-20
US20130273075A1 (en) 2013-10-17
EP1519749A1 (de) 2005-04-06
US20050288211A1 (en) 2005-12-29
US7553488B2 (en) 2009-06-30

Similar Documents

Publication Publication Date Title
ATE427758T1 (de) Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen
EA200802285A1 (ru) Бивалентные миметики smac и их применения
BRPI0407195A (pt) inibidor de histona desacetilase, composição, e, método para inibir histona desacetilase em uma célula
MX2024009001A (es) Inhibidores de la pcsk9 y metodos de uso de los mismos.
WO2012178208A3 (en) Selective inhibitors of histone deacetylase isoform 6 and methods thereof
BRPI1013388A2 (pt) composição de limpeza que compreende uma alfa-amilase e uma protease e método de limpeza de um tecido ou superficie dura
EP3354640A3 (de) Mif-hemmer und verwendungen davon
MX2009011069A (es) Mimeticos de smac diazo biciclicos y usos de los mismos.
PL1660507T5 (pl) Inhibitory proteazomu oraz sposoby ich stosowania
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
EA200801784A1 (ru) Ингибиторы е1 активирующих ферментов
BR112012018246A2 (pt) compostos de amida reversa como inibidores de proteína desacetilase e métodos de uso destes
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
WO2005069888A3 (en) Smac peptidomimetics and the uses thereof
DK1846424T3 (da) Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
MX375059B (es) Compuestos para el tratamiento de cancer.
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
WO2005117846A3 (en) Ice inhibitors for the treatment of autoinflammatory diseases
AR075130A1 (es) Composicion y metodo para reducir la corrosion de oxido blanco en sistemas de aguas industriales
EP2576536A4 (de) Hämatopoetische prostaglandin-d2-synthase-inhibitoren
EP2097377A4 (de) Renininhibitoren
PH12015500815A1 (en) Treatment of scleroderma using an inhibitor of cbp\catenin
UA98970C2 (ru) Соединения с функцией ингибирования тромбина и фармацевтические композиции на их основе

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties